Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

52.20 -0.20 (-0.38%)
Official Closing Price Updated: 7:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
48 49 Next >
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly
Via Benzinga
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union. 
Via The Motley Fool
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
Life sciences companies may be more immune to work-from-home shifts. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
Via Benzinga
Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook
The company's outlook for 2023 profit topped forecasts by 11 cents at the midpoint. 
Via Investor's Business Daily
A Preview Of Bristol-Myers Squibb's Earnings
Via Benzinga
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Bristol Myers Squibb Q4 Earnings And Revenues Surpass Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.82 per share. 
Via Talk Markets
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range
Via Benzinga
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For February 01
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock. 
Via The Motley Fool
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
2 Top Dividend Stocks to Buy in 2023 and Hold Forever
These companies are established leaders in their respective fields. 
Via The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
3 Buffett-Type Stocks to Buy Right Now
These stocks are good value buys for the long haul. 
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
5 Stocks You Can Confidently Invest $500 in Right Now
Any investor with $500 can buy these stocks with conviction. 
Via The Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
Via Benzinga
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing. 
Via Talk Markets
Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug
A cutting-edge cancer treatment from the drugmaker was recently approved in Japan to treat a type of lymphoma. 
Via The Motley Fool
7 Dividend-Paying Large-Cap Stocks to Buy in January
Now's the time to load up on these seven dividend-paying large-cap stocks, each of which has a forward dividend yield of at least 3%. 
Via InvestorPlace
3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off
These three healthcare stocks all deliver dependable dividends, with yields of 3% or more. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Via Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
Is Alexandria Real Estate Equity a Buy?
It's a great stock, but investors dislike the sector. 
Via The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks. 
Via InvestorPlace
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.